3 Year return
15.32%Investment Details
Calculate Returns
Based on past performance of this fund
Risk Involved
Your principal will be at
Very High Risk
Asset Under Management
₹7132.82 Cr.
Expense Ratio
0.92% (inclusive of GST)
Exit Load
1% if redeemed or switchd out on or efore completion of 1 Months from the date of allotment of units. NIl if redeemed or switched out after the completion of 1 Months from the date of allotment of units.
Tax Implications
Withdrawal within 1 year
Exit load + 15% tax on gains
Withdrawal after 1 year
10% tax on gains over ₹1 Lakh per financial year
Fund Holdings
Nippon India Mutual Fund Managers
SB
Sailesh Raj Bhan
Fund Manager since May 2018
Fund House Details
Nippon India Mutual Fund Asset management company
Peer Comparison
Comparison with other similar funds
Funds
|
3 Y Returns
|
ARQ Rating
|
---|---|---|
Invesco India PSU Equity Fund Direct Plan IDCW (Payout / Payout) |
42.14% |
0 |
Quant Infrastructure Fund IDCW Direct Plan Payout |
38.55% |
0 |
Invesco India Infrastructure Fund Direct Plan IDCW (Payout / Payout) |
37.43% |
0 |
Schemes by Nippon India Mutual Fund
List of mutual fund schemes by AMC
Hybrid . Arbitrage Fund
Nippon India Arbitrage Fund Direct Plan Monthly IDCW Payout
Hybrid . Arbitrage Fund
Nippon India Arbitrage Fund Direct Plan Monthly IDCW Reinvestment
Hybrid . Arbitrage Fund
Nippon India Arbitrage Fund Direct Plan IDCW Payout
Hybrid . Arbitrage Fund
Nippon India Arbitrage Fund Direct Plan IDCW Reinvestment
Hybrid . Arbitrage Fund
Nippon India Arbitrage Fund Direct Plan Growth
About Nippon India Pharma Fund Direct Plan Growth Plan Bonus Reinvestment
Nippon India Pharma Fund Direct Plan Growth Plan Bonus Reinvestment is managed by Nippon Life India Asset Management Limited, formerly known as Reliance Nippon Life Asset Management Limited. Categorised as Sectoral/Thematic Funds, this fund focuses on investing in companies within a specific sector or theme, in this case, the pharmaceutical sector. Sectoral funds like this one concentrate on specific industries, aiming to benefit from the growth potential of that sector. Nippon India Pharma Fund Direct Plan Growth Plan Bonus Reinvestment is an open-ended fund, meaning investors can buy or sell units of the fund at any time, within market hours.
Investment Objective of the Scheme
The primary investment objective of the Nippon India Pharma Fund Direct Plan Growth Plan Bonus Reinvestment is to seek long-term capital appreciation by primarily investing in equity and equity-related securities of companies in the pharmaceutical sector.
Key Features of The Fund
5-year return | 25.74% |
Expense Ratio | 0.92% |
Fund Manager | Sailesh Raj Bhan |
Fund Size | ₹7132.82 Cr |
Risk Profile | Very High |
Is This Scheme Right for Me?
This fund might be suitable for investors who have a positive outlook on the pharmaceutical sector and want to allocate a portion of their funds to this specific industry. Sectoral funds can offer higher potential returns but also come with concentrated risk. So, investors with low-risk tolerance should not consider this fund. Interested investors should also bear in mind the potential volatility of the pharmaceutical sector before making a decision.
AMC Contact Details
Name | Nippon India Mutual Fund |
Launch Date | June 1995 |
Addresss | Nippon Life India Asset Management Limited, 4th Floor, Tower A, Peninsula Business Park, Ganapatrao Kadam Marg, Lower Parel (W), Mumbai – 400 013 |
Contact | 1860 266 0111 |
customercare@nipponindiaim.in | |
Website | https://mf.nipponindiaim.com/ |
Disclaimer: Mutual funds are subject to market risk. Read all scheme-related documents carefully to make informed-decision.